trending Market Intelligence /marketintelligence/en/news-insights/trending/hcffqoipqb2yxmurzdectg2 content esgSubNav
In This List

Fennec's ear damage prevention drug gets US FDA fast track status

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Fennec's ear damage prevention drug gets US FDA fast track status

The U.S. Food and Drug Administration granted the fast-track designation to Fennec Pharmaceuticals Inc.'s Pedmark to prevent ototoxicity, or ear damage, as a side-effect of cisplatin chemotherapy in children with standard-risk hepatoblastoma.

Hepatoblastoma is a very rare cancerous tumor that starts in the liver and primarily affects children.

The fast track designation allows the FDA to accelerate the review process for drugs indicated to treat serious and life-threatening conditions.